ArticleCancer biomarkers : section A of Disease markers2018
Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- TP53 gene implications in prostate cancer evolution: potential role in tumor classification.Medicine and pharmacy reports · 2023Article
- miR-184 delays cell proliferation, migration and invasion in prostate cancer by directly suppressing DLX1.Experimental and therapeutic medicine · 2021Article
- miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer.Pharmaceutics · 2021Review
- Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance.Scientific reports · 2019Article
- MicroRNA‑195 suppresses rectal cancer growth and metastasis via regulation of the PI3K/AKT signaling pathway.Molecular medicine reports · 2019Article
- Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Review
- High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is the second most common cancer in men worldwide. Currently, prostate-specific antigen (PSA) test and digital rectal exam are the main screening tests used for PCa diagnosis. However, due to the low specificity of these tests, new alternative biomarkers such as deregulated RNAs and microRNAs have been implemented.
objectivesAberrant expressions of small heterodimer partner gene (SHP, NR0B2) and mir-141 are reported in various cancers. The aim of this study was to investigate the SHP and miR-141 expression level in tissue samples of prostate cancer.
methodsThe expression level of SHP gene and miR-141 was assessed by real time PCR and their relative amounts were calculated by the ΔΔCT method. Also, IHC technique was used to determine the expression level of SHP protein.
resultsThe miR-141 was significantly up-regulated in the samples of metastatic tumors compared to localized tumor samples (P< 0.001, 31.17-fold change). Tumor samples showed lower SHP mRNA expression levels than BPH samples (p= 0.014, 4.7-fold change). The results of paired t-test analysis showed there was no significant difference between the SHP gene expression in PCa samples and their matched tumor-adjacent normal tissue (p= 0.5).
conclusionsThe data obtained in our study confirm the involvement of miR-141 in PCa progression and metastasis. These effects could be mediated by AR via down-regulation of its co-repressor protein, i.e., SHP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.